NO20051263L - Ny anvendelse av benzotiazolderivater - Google Patents

Ny anvendelse av benzotiazolderivater

Info

Publication number
NO20051263L
NO20051263L NO20051263A NO20051263A NO20051263L NO 20051263 L NO20051263 L NO 20051263L NO 20051263 A NO20051263 A NO 20051263A NO 20051263 A NO20051263 A NO 20051263A NO 20051263 L NO20051263 L NO 20051263L
Authority
NO
Norway
Prior art keywords
sub
new use
benzothiazole derivatives
formula
disclosed
Prior art date
Application number
NO20051263A
Other languages
English (en)
Inventor
Peter Sjo
Peter Storm
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20051263L publication Critical patent/NO20051263L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Anvendelse av en forbindelse med formel (I) N HX s n-l-^ R^ (I) derX, A, B, D, Ri og Rj er som angitt i beskrivelsen samt farmasøytisk akseptable salter derav, for fremstilling av et medikament for terapi eller profylakse av sykdonmier eller tilstander der inhibering av kinase Itk aktiviteten er fordelaktig. Det beskrives nye forbindelser med formel (I) sammen med fremgangsmåter for deres fremstilling. Det beskrives videre preparater iimeholdende disse forbindelser. Forbindelsenes anvendelse i terapi er også beslcrevet.
NO20051263A 2002-08-14 2005-03-11 Ny anvendelse av benzotiazolderivater NO20051263L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0202429A SE0202429D0 (sv) 2002-08-14 2002-08-14 Novel Compounds
PCT/SE2003/001271 WO2004016600A1 (en) 2002-08-14 2003-08-13 Novel use of benzothiazole derivatives

Publications (1)

Publication Number Publication Date
NO20051263L true NO20051263L (no) 2005-05-12

Family

ID=20288724

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051263A NO20051263L (no) 2002-08-14 2005-03-11 Ny anvendelse av benzotiazolderivater

Country Status (16)

Country Link
US (1) US20060106015A1 (no)
EP (1) EP1539723B1 (no)
JP (1) JP2006504672A (no)
KR (1) KR20060002728A (no)
CN (1) CN1675189A (no)
AT (1) ATE327225T1 (no)
AU (1) AU2003248587A1 (no)
BR (1) BR0313407A (no)
CA (1) CA2495492A1 (no)
DE (1) DE60305514D1 (no)
IL (1) IL166412A0 (no)
MX (1) MXPA05001585A (no)
NO (1) NO20051263L (no)
SE (1) SE0202429D0 (no)
WO (1) WO2004016600A1 (no)
ZA (1) ZA200501098B (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070046148A (ko) * 2004-08-26 2007-05-02 와이어쓰 에스트로겐 작용제로서의 프로드러그 치환 벤족사졸
US7307094B2 (en) 2005-02-17 2007-12-11 Amr Technology, Inc. Benzoxazole carboxamides for treating CINV and IBS-D
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8093401B2 (en) 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8088928B2 (en) 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
EP1909910A1 (en) * 2005-08-04 2008-04-16 Sirtris Pharmaceuticals, Inc. Benzimidazole derivatives as sirtuin modulators
EP1990330B1 (de) * 2007-05-07 2011-06-29 Siemens Aktiengesellschaft Keramisches Pulver, keramische Schicht und Schichtsystem mit Pyrochlorphase und Oxiden
TW200916472A (en) 2007-06-20 2009-04-16 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
JP2011500778A (ja) 2007-10-25 2011-01-06 アストラゼネカ・アクチエボラーグ ピリジン及びピラジン誘導体−０８３
PE20120057A1 (es) 2008-12-19 2012-02-24 Sirtris Pharmaceuticals Inc Compuestos de tiazolopiridina moduladores de sirtuina
WO2013153539A1 (en) 2012-04-13 2013-10-17 Glenmark Pharmaceuticals S.A. Tricyclic compounds as tec kinase inhibitors
EP3060218A4 (en) 2013-10-25 2017-07-19 Pharmacyclics LLC Methods of treating and preventing graft versus host disease
MY190034A (en) 2015-03-06 2022-03-22 Beyondspring Pharmaceuticals Inc Method of treating cancer associated with a ras mutation
WO2017040617A1 (en) 2015-08-31 2017-03-09 Pharmacyclics Llc Btk inhibitor combinations for treating multiple myeloma
SG11201806583XA (en) 2016-02-08 2018-09-27 Beyondspring Pharmaceuticals Inc Compositions containing tucaresol or its analogs
EP3534938A2 (en) 2016-11-03 2019-09-11 Juno Therapeutics, Inc. Combination therapy of a t cell therapy and a btk inhibitor
KR102279347B1 (ko) 2016-12-15 2021-07-21 한국생명공학연구원 피리딘계 화합물을 유효성분으로 함유하는 dyrk 관련 질환의 예방 또는 치료용 약학적 조성물
WO2018111049A1 (ko) * 2016-12-15 2018-06-21 한국생명공학연구원 피리딘계 화합물을 유효성분으로 함유하는 dyrk 관련 질환의 예방 또는 치료용 약학적 조성물
EP3565812B1 (en) 2017-01-06 2023-12-27 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
CA3089226A1 (en) 2018-01-24 2019-08-01 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia via the administration of plinabulin
PT3762368T (pt) 2018-03-08 2022-05-06 Incyte Corp Compostos de aminopirazina diol como inibidores de pi3k-y
BR112020022185A2 (pt) 2018-05-03 2021-02-02 Juno Therapeutics Inc terapia de combinação de uma terapia de células t do receptor de antígeno quimérico (car) e um inibidor de quinase
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
CN112778155B (zh) * 2019-11-11 2023-08-11 大连万春布林医药有限公司 妥卡雷琐衍生物及其用途
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE581862A (no) * 1958-08-22
DE2145178C3 (de) * 1970-09-11 1975-12-11 Tokyo Tanabe Co., Ltd., Tokio 2-Phenyl-5-oder -6-benzothiazolylessigsäure-Verblndungen
JPS4932855B1 (no) * 1971-08-03 1974-09-03
DD150059A1 (de) * 1980-04-07 1981-08-12 Horst Hartmann Verfahren zur herstellung von hydroxyarylazolen
JPS62221679A (ja) * 1986-03-19 1987-09-29 Santen Pharmaceut Co Ltd ベンゾチアゾリン誘導体
DE4030511A1 (de) * 1990-09-27 1992-04-02 Basf Ag Hochtemperaturbestaendige, benzthiazolhaltige polyarylether
US5296486A (en) * 1991-09-24 1994-03-22 Boehringer Ingelheim Pharmaceuticals, Inc. Leukotriene biosynthesis inhibitors
EP1037632B1 (en) * 1997-11-10 2006-01-11 Bristol-Myers Squibb Company Benzothiazole protein tyrosine kinase inhibitors
US6436939B2 (en) * 2000-03-31 2002-08-20 Ortho-Mcneil Pharmaceutical, Inc. Method for using 2-aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzothiazoles as H3 antagonists
EP1345914A1 (en) * 2000-12-22 2003-09-24 AstraZeneca AB Therapeutic compounds
JP2002306916A (ja) * 2001-01-26 2002-10-22 Toray Ind Inc エアフィルタユニット

Also Published As

Publication number Publication date
BR0313407A (pt) 2005-07-05
DE60305514D1 (de) 2006-06-29
JP2006504672A (ja) 2006-02-09
ATE327225T1 (de) 2006-06-15
KR20060002728A (ko) 2006-01-09
WO2004016600A1 (en) 2004-02-26
ZA200501098B (en) 2006-12-27
SE0202429D0 (sv) 2002-08-14
US20060106015A1 (en) 2006-05-18
CA2495492A1 (en) 2004-02-26
CN1675189A (zh) 2005-09-28
MXPA05001585A (es) 2005-04-25
IL166412A0 (en) 2006-01-15
EP1539723A1 (en) 2005-06-15
AU2003248587A1 (en) 2004-03-03
EP1539723B1 (en) 2006-05-24

Similar Documents

Publication Publication Date Title
NO20051263L (no) Ny anvendelse av benzotiazolderivater
SE0202462D0 (sv) Novel use
NO20024014D0 (no) Ny bruk av fenylheteroalkylaminderivater
NO20055565L (no) Anvendelse av derivater av 2,4-dihydro-[1,2,4]triazol-3-thion som inhibitorer av enzymet myeloperoksidase (MPO)
NO20100939L (no) Tioksantinderivater som myeloperoksidaseinhibitorer
SE0104334D0 (sv) Therapeutic agents
IL165264A (en) Protein kinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating protein kinase-associated diseases
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
NO20060147L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
GB0112348D0 (en) Compounds
MY133527A (en) Isoquinoline derivatives
SE0201837D0 (sv) Chemical compounds
SE0402591D0 (sv) Novel use
NO20024013D0 (no) Ny anvendelse av fenylheteroalkylaminderivater
BRPI0415546A (pt) composto, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, e de distúrbios
DE60233578D1 (de) Phosphorenthaltende Verbindugnen mit antithrombitische Wirkung
SE0201193D0 (sv) Novel use

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application